Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.

Tytuł :
A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.
Autorzy :
Quinten C; Quality of Life Department, European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Martinelli F
Coens C
Sprangers MA
Ringash J
Gotay C
Bjordal K
Greimel E
Reeve BB
Maringwa J
Ediebah DE
Zikos E
King MT
Osoba D
Taphoorn MJ
Flechtner H
Schmucker-Von Koch J
Weis J
Bottomley A
Pokaż więcej
Corporate Authors :
Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups
Źródło :
Cancer [Cancer] 2014 Jan 15; Vol. 120 (2), pp. 302-11. Date of Electronic Publication: 2013 Oct 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
MeSH Terms :
Quality of Life*
Neoplasms/*etiology
Neoplasms/*mortality
Aged ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Self-Assessment
Contributed Indexing :
Investigator: W Albrecht; J Becker; R Coleman; T Conroy; R de Wit; A Eggermont; S Fossa; G Giaccone; J Horiot; F Keuppens; C Koehne; J Lefebvre; F Levi; O Oosterhof; M Piccart; P Postmus; H Schmoll; E Smit; T Splinter; M Taphoorn; P Therasse; J Van Meerbeeck; H Van Poppel
Keywords: cancer; multi trial; patient-reported outcomes; prognostic factors; quality of life
Entry Date(s) :
Date Created: 20131016 Date Completed: 20140225 Latest Revision: 20140108
Update Code :
20210209
DOI :
10.1002/cncr.28382
PMID :
24127333
Czasopismo naukowe
Background: The objective of this study was to examine the prognostic value of baseline health-related quality of life (HRQOL) for survival with regard to different cancer sites using 1 standardized and validated patient self-assessment tool.
Methods: In total, 11 different cancer sites pooled from 30 European Organization for Research and Treatment of Cancer (EORTC) randomized controlled trials were selected for this study. For each cancer site, univariate and multivariate Cox proportional hazards modeling was used to assess the prognostic value (P< .05) of 15 HRQOL parameters using the EORTC Core Quality of Life Questionnaire (QLQ-C30). Models were adjusted for age, sex, and World Health Organization performance status and were stratified by distant metastasis.
Results: In total, 7417 patients completed the EORTC QLQ-C30 before randomization. In brain cancer, cognitive functioning was predictive for survival; in breast cancer, physical functioning, emotional functioning, global health status, and nausea and vomiting were predictive for survival; in colorectal cancer, physical functioning, nausea and vomiting, pain, and appetite loss were predictive for survival; in esophageal cancer, physical functioning and social functioning were predictive for survival; in head and neck cancer, emotional functioning, nausea and vomiting, and dyspnea were predictive for survival; in lung cancer, physical functioning and pain were predictive for survival; in melanoma, physical functioning was predictive for survival; in ovarian cancer, nausea and vomiting were predictive for survival; in pancreatic cancer, global health status was predictive for survival; in prostate cancer, role functioning and appetite loss were predictive for survival; and, in testis cancer, role functioning was predictive for survival.
Conclusions: The current results demonstrated that, for each cancer site, at least 1 HRQOL domain provided prognostic information that was additive over and above clinical and sociodemographic variables.
(© 2013 American Cancer Society.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies